DOCTOR Recross: The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study

Sponsor
Aarhus University Hospital Skejby (Other)
Overall Status
Unknown status
CT.gov ID
NCT02234804
Collaborator
Abbott Medical Devices (Industry), Medtronic (Industry)
60
3
4
43.1
20
0.5

Study Details

Study Description

Brief Summary

Prospective, controlled, double randomized, non-blinded, multicenter, investigator initiated, academic superiority trial comparing optical coherence tomography (OCT) guided vs. angiography guided wire recrossing in jailed side branches (SB) (1. randomization 1:1)(superiority) and comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium (2. randomization 1:1) (superiority). Acute primary endpoint and 30 days clinical follow-up.

Hypothesis: OCT guided wire recrossing in bifurcation stenting results in less malapposed struts in the segment facing the SB ostium.

Secondary hypothesis: Treatment by Medtronic Resolute Integrity stent results in less malapposed struts at the bifurcation segment compared to treatment by the Abbott Xience Prime stent.

Condition or Disease Intervention/Treatment Phase
  • Device: Xience Prime Stent
  • Device: Medtronic Resolute Integrity stent
  • Procedure: Angiography
  • Procedure: OCT
N/A

Detailed Description

Purpose:

To assess the ability of OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.

To compare stent strut apposition after treatment by two different stent designs using both guiding strategies of wire recrossing.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study
Study Start Date :
Jul 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2016
Anticipated Study Completion Date :
Feb 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Medtronic Resolute Integrity stent

Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium

Procedure: Angiography
Other Names:
  • CAG
  • Procedure: OCT

    Experimental: OCT

    OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.

    Device: Xience Prime Stent
    Other Names:
  • Stent
  • Device: Medtronic Resolute Integrity stent
    Other Names:
  • Stent
  • Active Comparator: Angiography

    Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.

    Device: Xience Prime Stent
    Other Names:
  • Stent
  • Device: Medtronic Resolute Integrity stent
    Other Names:
  • Stent
  • Active Comparator: Xience Prime stent

    Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium

    Procedure: Angiography
    Other Names:
  • CAG
  • Procedure: OCT

    Outcome Measures

    Primary Outcome Measures

    1. Cross sectional stent strut malapposition in the main vessel bifurcation segment facing the side-branch ostium compared for optical coherence tomography and angioguided recrossing strategy [Baseline]

    Secondary Outcome Measures

    1. Procedural: 1. Success in recrossing into designated strut hole when visible and indicated [Baseline]

    2. Procedural: 2. Procedure duration (sheath insertion to closure device excluding treatment of other vessels) [Baseline]

    3. Procedural: 3. Contrast use [Baseline]

    4. Procedural: 4. Fluoroscopy time [Baseline]

    5. Optical coherence tomography endpoints: 5. Malapposition in the main vessel segment limited by and facing the side-branch ostium compared for stent type (second randomization) [Baseline]

    6. Optical coherence tomography endpoints: Malapposition in the proximal and distal main vessel segments and in the quadrants opposite to the side branch origin for stent type and recross strategy [Baseline]

    7. Optical coherence tomography endpoints: Distance between malapposed strut and vessel wall in all segments for stent type and recross strategy [Baseline]

    8. Optical coherence tomography endpoints: Minimum expansion of the stents expressed as absolute area and percentage of the closest reference area, for stent type and recross strategy [Baseline]

    9. Optical coherence tomography endpoints: Ostial stent area stenosis by optical coherence tomography (side branch reference area by 3D QCA) [Baseline]

    10. Angiographic endpoints: Segmental assessment; Proximal edge, proximal main vessel, bifurcation segment, distal main vessel, distal edge, ostial 5 mm of side branch. Pre and post side branch intervention [Baseline]

    11. Ostial side branch area stenosis [Baseline]

    12. Ostial side branch acute gain after main vessel (MV) stenting [Baseline]

    13. Minimal luminal area of all segments [Baseline]

    14. Angiographic area stenosis of all other segments [Baseline]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Stable or unstable angina pectoris or silent angina pectoris.

    • De novo coronary bifurcation lesions at "LAD/diagonal", "Cx/obtuse marginal", "right coronary artery (RCA)- posterior descending artery (PDA)/posterolateral branch" or "left main (LM)/Cx/LAD".

    • All Medina classes except Medina 0.0.1.

    • Diameter of side branch ≥2.5 mm.

    • Diameter stenosis >50% by operator's visual assessment

    • Signed informed consent

    Exclusion Criteria:
    • ST-elevation infarction within 48 hours.

    • Side branch lesion length >5 mm.

    • Expected survival < 1 year

    • Severe heart failure (NYHA≥III)

    • S-creatinine >120 µmol/l.

    • Allergy to Contrast media, Aspirin, Clopidogrel, Ticagrelor, Ticlopidine, Everolimus or Zotarolimus.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospitals Leuven Leuven Belgium 3000
    2 Aarhus University Hspital Aarhus N Denmark 8200
    3 Royal Brompton Hospital London United Kingdom

    Sponsors and Collaborators

    • Aarhus University Hospital Skejby
    • Abbott Medical Devices
    • Medtronic

    Investigators

    • Principal Investigator: Niels R Holm, MD, Aarhus University Hospital Skejby

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Niels Ramsing Holm, MD, Aarhus University Hospital Skejby
    ClinicalTrials.gov Identifier:
    NCT02234804
    Other Study ID Numbers:
    • 1-10-72-111-13
    First Posted:
    Sep 9, 2014
    Last Update Posted:
    Oct 6, 2015
    Last Verified:
    Oct 1, 2015
    Keywords provided by Niels Ramsing Holm, MD, Aarhus University Hospital Skejby
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 6, 2015